Anadys Pharmaceuticals (ANDS) Acquired by Roche for $3.70/Share, 256% Premium
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Join SI Premium – FREE
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) entered into a definitive merger agreement to be acquired by Roche (OTC: RHHBY) for $3.70 per share in cash.
The offer represents a 256% premium over Friday's closing price.
The tender offer is expected to close within the fourth quarter of 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
The offer represents a 256% premium over Friday's closing price.
The tender offer is expected to close within the fourth quarter of 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Evolution Petroleum closes $16M Midland Basin royalty acquisition
- Bunker Hill Mining to acquire Silver47 in all-share merger deal
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
